• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DJO® Acquires Trilliant Surgical

    1/19/21 7:00:00 PM ET
    $CFX
    Fluid Controls
    Capital Goods
    Get the next $CFX alert in real time by email

    DALLAS--(BUSINESS WIRE)--DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced the acquisition of Trilliant Surgical®, a national provider of foot and ankle orthopedic implants. The acquisition of Trilliant Surgical’s leading product technologies and clinical efficacy supports DJO’s focused expansion into the adjacent high-growth $1 billion US foot and ankle market.

    In addition to having a broad product portfolio that covers the full universe of foot recon/fixation procedures, Trilliant Surgical is the only provider of the novel Arsenal Foot Plating System™. With unique features designed for greater flexibility and speed of implant placement supporting ease of use, less waste and reduced OR time, Arsenal is poised to be a plating leader.

    “Trilliant’s market-leading portfolio of foot and ankle solutions complements our acquisition of the STAR™ system and creates a dedicated foot and ankle business that significantly expands our mission of Powering Motion,” said Brady Shirley, CEO of DJO. “We are committed to building our Reconstructive segment and believe that the foot and ankle space is a great fit for our focused innovation and solutions approach that has allowed DJO to be a growth leader in the upper extremity market for many years.”

    Among the factors driving the high-growth foot and ankle market are a rapidly growing elderly population, sports-related injuries, and the increasing prevalence of diabetes and related lower-extremity conditions. The Arsenal system addresses a number of mid- and hind-foot procedures and will be extended to ankle, with the potential to achieve significant additional penetration of medical procedures.

    “As a foot and ankle champion since 2007, we are excited to join the DJO family and expand Trilliant Surgical’s positive patient impact globally,” said Jon Olson, CEO of Trilliant Surgical. “DJO’s unparalleled commitment to new product development, their iconic brands and strong growth trajectory will accelerate Trilliant’s ability to grow, innovate and improve patient outcomes.”

    Total Ankle Replacement

    DJO’s expansion into foot and ankle surgery complements its strong position in Total Ankle Replacements; in 2020, DJO acquired the Scandinavian Total Ankle Replacement (STAR) System, which holds a leading position in the global ankle arthroplasty market.

    Ankle replacement surgeries have grown over the last decade, and according to Musculoskeletal Clinical Regulatory Advisors, as of February 2011 all public insurance programs, workers compensation and 92% of commercial insured patients have access to ankle replacement procedures when deemed medically necessary by a trained surgeon. 1

    For more information, visit djoglobal.com/TrilliantSurgical

    Reference:

    1. SmartTrak® Foot & Ankle Reimbursement: https://app.smarttrak.com/markets/qs/fd52946dc2bd8b02ac1002535b62cf35

    England & Company served as exclusive financial advisor to the sellers.

    About DJO®

    DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.

    CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS

    This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning DJO’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on DJO’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause DJO’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers, and other impacts on DJO’s business and ability to execute business continuity plans, and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. DJO disclaims any duty to update the information herein.

    Get the next $CFX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CFX

    DatePrice TargetRatingAnalyst
    3/2/2022$8.00 → $7.00Sector Perform
    RBC Capital
    2/23/2022$58.00 → $52.00Buy
    Stifel
    2/8/2022Buy → Neutral
    Seaport Global
    1/28/2022$51.00 → $45.00Equal-Weight
    Morgan Stanley
    1/14/2022$56.00 → $51.00Equal-Weight
    Morgan Stanley
    1/6/2022$45.00Hold
    Loop Capital
    11/5/2021$57.00 → $60.00Overweight
    Keybanc
    10/20/2021$12.00 → $9.00Outperform → Sector Perform
    RBC Capital
    More analyst ratings

    $CFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on Canfor Pulp Products with a new price target

      RBC Capital reiterated coverage of Canfor Pulp Products with a rating of Sector Perform and set a new price target of $7.00 from $8.00 previously

      3/2/22 7:16:55 AM ET
      $CFX
      Fluid Controls
      Capital Goods
    • Stifel reiterated coverage on Colfax with a new price target

      Stifel reiterated coverage of Colfax with a rating of Buy and set a new price target of $52.00 from $58.00 previously

      2/23/22 8:55:36 AM ET
      $CFX
      Fluid Controls
      Capital Goods
    • Colfax downgraded by Seaport Global

      Seaport Global downgraded Colfax from Buy to Neutral

      2/8/22 6:36:17 AM ET
      $CFX
      Fluid Controls
      Capital Goods

    $CFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation

      Wilmington, DE, April 05, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation ("Enovis" or the "Company") (NYSE:ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the "Separation") of its fabrication technology business into an independent, publicly traded company, ESAB Corporation ("ESAB") (NYSE:ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued and outstanding shares of Enovis common stock at a one-for-three ratio. Enovis and ESAB common stock will each begin regular-way trading today, April 5, 2022, on t

      4/5/22 6:00:00 AM ET
      $CFX
      Fluid Controls
      Capital Goods
    • ESAB Set to Join S&P MidCap 400; PROG Holdings to Join S&P SmallCap 600

      NEW YORK, March 30, 2022 /PRNewswire/ -- ESAB Corp. (NYSE:ESAB) will be added to the S&P MidCap 400 effective prior to the opening of trading on Tuesday, April 5. Effective prior to the opening of trading on Wednesday, April 6, S&P MidCap 400 constituent PROG Holdings Inc. (NYSE:PRG) will replace Fiesta Restaurant Group Inc. (NASD: FRGI) in the S&P SmallCap 600. S&P MidCap 400 constituent Colfax Corp. (NYSE:CFX) is spinning off ESAB in a transaction expected to be completed on April 5. Post spin-off, Colfax will be renamed Enovis Corp. (NYSE:ENOV) and will remain in the S&P MidCap 400. PROG Holdings is more representative of the small-cap market space and Fiesta Restaurant Group is no longer

      3/30/22 8:21:00 PM ET
      $CFX
      $FRGI
      $PRG
      $SPGI
      Fluid Controls
      Capital Goods
      Restaurants
      Consumer Discretionary
    • Colfax Announces Board of Directors for Post-Spinoff ESAB

      Wilmington, DE, March 28, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company which will renamed Enovis Corporation ("Enovis") following the expected April 4, 2022 consummation of the Company's previously announced spin-off of its fabrication technology business (the "Separation"), which will operate as ESAB Corporation ("ESAB") after the Separation, today announced the future composition of the full ESAB Board of Directors (the "Board"). Following the Separation, Mitchell P. Rales will serve as chairman of the Board, and current Colfax directors Patrick W. Allender, Rhonda L. Jordan, Didier Teirlinck and Rajiv Vinnakota will serve as directo

      3/28/22 6:30:00 AM ET
      $CFX
      Fluid Controls
      Capital Goods

    $CFX
    SEC Filings

    See more
    • Colfax Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Enovis CORP (0001420800) (Filer)

      6/30/22 8:23:02 AM ET
      $CFX
      Fluid Controls
      Capital Goods
    • SEC Form 11-K filed by Colfax Corporation

      11-K - Enovis CORP (0001420800) (Filer)

      6/29/22 3:02:16 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • Colfax Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Enovis CORP (0001420800) (Filer)

      6/13/22 4:14:55 PM ET
      $CFX
      Fluid Controls
      Capital Goods

    $CFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Kleckner John sold $2,496 worth of shares (44 units at $56.73), decreasing direct ownership by 3% to 1,661 units (for tax liability)

      4 - Enovis CORP (0001420800) (Issuer)

      7/21/22 8:00:15 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • SEC Form 4: Perfall A Clayton was granted 432 shares, increasing direct ownership by 1% to 31,073 units

      4 - Enovis CORP (0001420800) (Issuer)

      7/1/22 7:00:22 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • SEC Form 4: Lalor Angela S was granted 319 shares, increasing direct ownership by 16% to 2,363 units

      4 - Enovis CORP (0001420800) (Issuer)

      7/1/22 7:00:17 PM ET
      $CFX
      Fluid Controls
      Capital Goods

    $CFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Colfax Corporation

      SC 13G - Enovis CORP (0001420800) (Subject)

      4/21/22 3:32:21 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • SEC Form SC 13G/A filed by Colfax Corporation (Amendment)

      SC 13G/A - Colfax CORP (0001420800) (Subject)

      3/11/22 2:13:51 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • SEC Form SC 13G/A filed by Colfax Corporation (Amendment)

      SC 13G/A - Colfax CORP (0001420800) (Subject)

      2/9/22 3:43:31 PM ET
      $CFX
      Fluid Controls
      Capital Goods

    $CFX
    Financials

    Live finance-specific insights

    See more
    • Colfax Corporation Announces Fourth Quarter and Full Year 2021 Results

      Strong operating performance supported $0.06 EPS from continuing operations and $0.59 of adjusted EPSAchieved a strong quarter of cash flow, contributing to full year operating cash flow of $356 million and free cash flow of $277 millionPositioned for separation into two independent public companies near the end of the first quarter 2022 with strong growth outlooks for both businesses Wilmington, DE, Feb. 22, 2022 (GLOBE NEWSWIRE) --  Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the fourth quarter and fiscal year 2021 and provided additional updates. The Company reported fourth quarter net income from c

      2/22/22 6:00:00 AM ET
      $CFX
      Fluid Controls
      Capital Goods
    • Colfax Schedules Fourth Quarter and Fiscal Year 2021 Earnings Release and Conference Call

            Wilmington DE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter and fiscal year 2021 on the morning of Tuesday, February 22, 2022. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 7466839 and through webcast via Colfax's website www.colfaxcorp.com under the "Investors" section. Colfax's financial results

      1/20/22 5:00:23 PM ET
      $CFX
      Fluid Controls
      Capital Goods
    • Colfax Corporation Announces Third Quarter 2021 Results

                                                     Posted $0.17 EPS from continuing operations and $0.54 of adjusted EPSIncreased sales 20% to $966 million including a 15% organic sales-per-day improvementReported strong progress on integration of acquisitionsAnnounced continued progress to Q1 2022 separation including new post-separation name for MedTech growth company WILMINGTON, DE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the third quarter of 2021 and provided other updates. The Company reported third quarter net income from continuing operations of $27 million, or $0

      11/4/21 6:00:00 AM ET
      $CFX
      Fluid Controls
      Capital Goods